4.5 Group Recommendations
4.5.3 Discussion
5.3.1 Methods of studying tolerance in MHC-II transgenic animals Applicants: Antitope Limited.
Inventor: Matthew Baker
Right of ownership: Deed of assignment between Matthew Baker and Antitope Limited.
55 Patent family details:
Country Application No./Patent No. Case Status
Australia 2005308597 Granted
Canada 2589163 Pending
China 200580039918.6 Pending
EPO 1814386 Granted
India 3586/DELNP/2007 Pending
Japan 4964781 Granted
Republic of Korea 10-2007-7014189 Proceeding to grant
USA 11/719876 Pending
Summary of invention
The family claims priority from a GB application filed 23 November 2004. A PCT application was filed on 23 November 2005 and published as WO2006/056769. Normal expiry is 2025. In Europe, the patent has been validated in Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and United Kingdom.
This family relates to methods for testing immunogenicity of a variant antigen in a mammal transgenic for human MHC class II and tolerised to the native antigen.
5.3.2 Human antibodies and proteins Ownership: Antitope Limited.
Inventors: Timothy David Jones; Matthew Paul Baker
Right of ownership: Deeds of assignment between Timothy David Jones and Antitope Limited, and between Matthew Baker and Antitope Limited.
Patent family details:
Country Application No./Patent No. Case Status
Australia (divisional application) 2012209017 Pending
Canada 2596833 Pending
China CN101115771A Granted
EPO (divisional application) 2388271 Pending
EPO 1844074 Granted
Hong Kong 1109636 Granted
India (divisional application) 8684/DELNP/2013 Pending
India 257815 Granted
Japan (divisional application) 5461643 Granted
Japan 2007-553693 Pending
Republic of Korea 10-2007-7019951 Granted
USA 11/815507 Pending
Summary of invention
The family claims priority from three GB applications filed 3 February 2005, 16 February 2005 and 5 April 2005. A PCT application was filed on 3 February 2006 and published as WO2006/082406.
Normal expiry is 2026. In Europe, the granted patent has been validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Spain, Sweden, Switzerland and United Kingdom.
This family relates to composite antibodies wherein the heavy and light chain variable regions of the modified antibody are each composed of two or more segments of amino acid sequence from one or more other antibodies, and wherein the segments are neither whole CDRs nor framework regions.
5.3.3 T cell assays
Applicants: Antitope Limited.
Inventors: Matthew Baker; Francis J. Carr; Alyson Rust; Laura Davies.
Right of ownership: Deed of assignment between Matthew Baker and Antitope Limited, and Francis James Carr and Antitope Limited. For Alyson Rust and Laura Davies, by employment.
Patent family details:
Country Application No./Patent No. Case Status
Australia (divisional application) 2013206786 Pending
Canada 2644540 Pending
China CN101427135A Pending
EPC 1989544 Granted
Hong Kong 1126274 Granted
India 8291/DELNP/2008 Pending
Japan 5161798 Granted
Republic of Korea 10-1361887 Granted
Russian Federation 2476884 Granted
Singapore (divisional application) 201101440-4 Proceeding to grant
Singapore 200806371-1 Pending
USA 12/281129 Pending
Summary of invention
The family claims priority from three GB applications filed 2 March 2006, 29 September 2006 and 11 October 2006. A PCT application was filed on 2 March 2007 and published as WO2007/099341.
Normal expiry is 2027. In Europe, the granted patent has been validated in Austria, Belgium, the Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and United Kingdom.
This family relates to methods for measuring helper T cell responses to a test substance using a sample of antigen presenting cells, which have been depleted of regulatory T cells.
5.3.4 T cell epitope databases Applicants: Antitope Limited.
Inventors: Frank Carr; Matthew Paul Baker.
Right of ownership: Deed of assignment between Francis James Carr and Antitope Limited, and between Matthew Paul Baker and Antitope Limited.
Patent family details:
Country Application No./Patent No. Case Status
Australia 2007306102 Granted
Canada 2666320 Pending
China CN101573711A Pending
EPO 2080138 Pending
India 2562/CHENP/2009 Pending
Japan 5456477 Granted
Republic of Korea 10-2009-7009517 Pending
Russian Federation 2009113455 Pending
Singapore (divisional application) 201107295-6 Pending
USA (continuation application) 13/562854 Pending
Summary of invention
The family claims priority from two GB applications filed on 11.10.06. A PCT application was filed on 11.10.07 and published as WO2008/044032. Normal expiry is 2027.
This family relates to methods for detection of helper T cell epitopes in a test protein by analysis of 9mers from the test protein sequence. The method involves looking for matches for residues 2,3,5, and 8 between one or more T cell epitopes and a 9mer sequence in the test protein sequence and analysis and detection of binding by the same 9mer sequence of the test protein to MHC class II molecules.
57 5.3.5 Humanised Anti CTLA-4 Antibodies
Applicants: Antitope Limited
Inventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr.
Right of ownership: By employment. Confirmatory assignment effective 8 March 2011 between Timothy Jones, Robert Holgate, Francis Carr, and Antitope Limited.
Patent family details:
This patent family was prepared and filed by Kilburn & Strode. It was transferred to Abel & Imray for handling in 2013. The family claims priority from a GB application and a US application, both filed 9 March 2011. A PCT application was filed on 9 March 2012 and published as WO2012/120125.
Normal expiry is 2032.
The pending patent applications describe antibodies against human CTLA-4, that block binding of human CTLA-4 to human B7 and thereby induce, augment or prolong an immune response, or that suppress an immune response through induction of regulatory T-cells or down-regulation of CTLA-4.
5.3.6 Humanised anti CD52 Antibodies Applicants: Antitope Limited
Inventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr.
Right of ownership: By employment. Confirmatory assignment effective 31 May 2011 between Timothy Jones, Robert Holgate, Francis Carr, and Antitope Limited.
Patent family details:
Summary of the invention
This patent family was prepared and filed by Kilburn & Strode. It was transferred to Abel & Imray for handling in 2013. The family claims priority from a GB application and a US application, both filed 1 June 2011. A PCT application was filed on 1 June 2012 and published as WO2012/164063.
Normal expiry is 2032.
The pending patent applications describe anti-human CD52 antibodies defined by specific CDR sequences and their use for treating CD52-related diseases, for example chronic lymphocytic leukaemia (CLL) and other leukaemias.
5.4 Warwick Effect Polymers Limited. - Patent Portfolio 5.4.1 Polymerisation Catalysts and Process
Applicants: Warwick Effect Polymers Limited.
Inventor: David Mark Haddleton.
Right of ownership: By employment with the University of Warwick and Intellectual Property Assignment, Patent Licence and IP Pipeline Deed between the University of Warwick and Warwick Effect Polymers Ltd dated 2 June 2005.
Patent Family Table:
Country Application No./Patent No. Status
Canada 2258006/2258006 Granted
EPC 97926105.4/0906342 Granted
United States 09/202,096/6310149 Granted
Summary of the invention
The patent family claims priority from two GB priority applications filed on 12 June 1996 and 7 April 1997. A PCT application was filed on 12 June 1997 and published as WO1997/47661. Normal expiry is 2017, although the US patent will expire in 2018. The granted European patent was validated in the UK, France and Germany.
The patent protects novel catalysts and their use in methods that produce polymers such as plastics with improved properties such as consistent polymer length. This in turn allows the production of higher quality products made from the polymers.
The United States patent was re-examined, and the European patent opposed, because of challenges by Carnegie Mellon University. The European patent EP 0906342 B is still being opposed at the European Patent Office.
5.4.2 Comb polymers comprising alkoxy polyether side groups and catalysts and methods for producing them
Applicants: Warwick Effect Polymers Limited.
Inventors: David Haddleton, François LeColley, Lei Tao, Guiseppe Mantovani, Adrian Carmichael, Adam Peter Jarvis, Andrew Gregory Steward.
Right of ownership: By employment and studentships with The University of Warwick and Intellectual Property Assignment, Patent Licence and IP Pipeline Deed between the University of Warwick and Warwick Effect Polymers Ltd dated 2 June 2005 in the case of David Haddleton, François LeColley, Lei Tao, Guiseppe Mantovani and Adrian Carmichael. By employment with Warwick Effect Polymers Limited. in the case of Adam Peter Jarvis and Andrew Gregory Steward.
Patent family table:
Country Application No./Patent No. Status
Canada 2530001/2530001 Granted
India 169/KOL NP/06/236508 Granted
Japan 2006-516436/5264073 Granted
Japan (divisional application) 2007-519858/5017107 Granted
EPO 04742963/1646661 Granted
USA 11/498,525/8436104 Granted
59 Summary of the invention
The family claims priority from a GB application filed on 20 June 2003. A PCT application was filed on 18 June 2004 and published as WO2004/113394. Normal expiry is 2024 although the US granted patent will expire in 2027. The granted European patent is validated in France, Germany, Italy, Spain, Switzerland, and the United Kingdom.
This patent family has claims directed to methods of producing comb polymers, and particularly pharmaceutically useful polymers with side groups such as polyethylene glycol.
5.5 Trade Marks
This section lists those marks which are relevant to Abzena’s core technology.
5.5.1 PolyTherics Limited – Trade Marks handled by Abel & Imray
PolyTherics Limited’s overall strategy has been to file trade mark applications for the core marks for its technologies in the European Union and the United States, using the following specifications in Europe and a more precisely defined specification in the US as required by local examination practice:
1 Chemical preparations and substances for use as pharmaceutical intermediates; chemical products for use in pharmaceuticals.
5 Pharmaceutical preparations and substances; chemical preparations for medical use.
42 Pharmaceutical research services; biomedical research services; chemical research services; development of pharmaceutical preparations a d medicines; laboratory services;
medical laboratory services.
45 Rental and licensing of intellectual property.
Trade Marks TheraPEG, HiPEG and CyPEG
These marks have been registered as Community Trade Marks (CTM) and US Trade Mark Registrations. Evidence of use will need to be filed in due course in respect of the US Registrations between the fifth and sixth year following the date of registration. There is also a pending application in India for the mark TheraPEG.
Trade Mark ThioBridge
The CTM proceeded to registration in respect of Class 45 services. The corresponding US Application has been provisionally accepted for registration in Classes 1, 5, 42 and 45.
A schedule of these marks follows.
Country Application
No. Application
Date Registration
No. Registration
Date Mark Status Local Classes
EC 008221574 16/04/2009 008221574 27/01/10 CyPEG Registered 01, 05, 42, 45
USA 77/833200 23/09/2009 4235640 06/11/2012 CyPEG Registered 01, 05, 42, 45
USA 77/833191 23/09/2009 4235639 06/11/2012 HiPEG Registered 01, 05, 42, 45
EC 008221434 16/04/2009 008221434 11/12/2009 HiPEG Registered 01, 05, 42
EC 005281936 29/08/2006 005281936 25/05/2007 TheraPEG Registered 01, 05, 42 USA 77/833175 23/09/2009 3949768 26/04/2011 TheraPEG Registered 01, 05, 42, 45
India 2324467 01/05/2012 TheraPEG Pending 01, 05, 42, 45
EC 011303245 29/10/2012 011303245 14/05/2013 THIOBRIDGE Registered 45
USA 85/775260 08/11/2012 THIOBRIDGE Pending 01, 05, 42, 45
5.5.2 PolyTherics Limited - Marks handled elsewhere
PolyTherics Limited has recently arranged filing of a CTM Application (through “The Trademark Helpline”) and a US Application (through Marcaria) claiming priority from the CTM Application for the markAbzena with the following details.
Country Application
No. Application
Date Registration
No. Registration
Date Mark Status Local Classes
EC 012688057 12/03/2014 Abzena Published 01, 05, 42, 44
USA 86/234440 27/03/2014 Abzena Pending
examination 01, 05, 42, 44
5.5.3 Warwick Effect Polymers Limited (“WEP”)
Warwick Effect Polymers Limited is the owner of the following trade mark, the details of which, together with an advisory note set out below, have been supplied by the firm Withers & Rogers which handled their prosecution and manages the WEP portfolio.
WEP’s trade mark strategy has been to file trade mark applications to protect the main marks used in the European Union and United States of America, using the following specification (with Class 1 being narrowed to "chemicals for use in industry and science, namely, chemicals in the form of polymers for use in the manufacture of pharmaceuticals" in the US, which is standard practice to avoid objection to registration by the USPTO):
Class 1: Chemicals used in industry and science; chemical preparations for scientific